Answers are grounded in this paper and cite their sources.
BACKGROUND: TGF-beta has been identified as a key factor in the progression of various diseases, in particular cancer and fibrosis. The signaling of TGF-beta can be modulated through three distinct strategies: using antisense nucleotides that block TGF-beta mRNA (trabedersen (AP 12009)), using monoclonal antibodies to block TGF-beta isoforms (lerdelimumab, metelimumab) or using small molecule inhibitors of the TGF-beta receptor 1 (TGF-betaR1 or ALK-5). OBJECTIVE: This review focuses on small molecules and summarizes the most recent TGF-betaR1 inhibitors reported in the patent literature. METHODS: We searched and analyzed the patent literature claiming chemical matter for TGF-betaR1 inhibition from the 1(st) of January 2005 to the 1(st) of January 2009. RESULTS/CONCLUSIONS: The inhibition of TGF-beta has recently been clinically validated with antisense nucleotide trabedersen. Small molecules inhibitors of TGF-betaR1 that are now in Phase I clinical trials and in preclinical stage are, therefore, of high interest and could provide a more versatile route to TGF-beta modulation through oral dosing while maintaining the same therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Bonafoux et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: